09.22.26 -- How Regeneron Navigates Early Cell And Gene Therapy Quality Risks

Address the rising gene therapy demands with an innovative perfusion strategy that significantly boosts cell density and viral vector yields to pave the way for scalable, efficient manufacturing.

Automated fill-finish systems protect sensitive cell therapies using low-shear handling to maintain dose uniformity, cell viability, and process consistency across every batch.

Autologous cell therapies require absolute process repeatability. Explore how automated cryovial filling protects cell viability and eliminates manual variability.

Metal-sensitive analytes often suffer from poor recovery and distorted peak shapes. Learn how inert hardware improves sensitivity and chromatographic performance for challenging analyses.

The coming decade will transform gene therapy through novel delivery methods, advanced analytical testing, and intensified upstream and downstream bioprocessing models.

AAV vectors hold promise for gene therapy, but removing product-related impurities remains a challenge. Uncover how cell line development and process optimization are advancing rAAV production.

Evaluate the impact of peptone supplementation on adenovirus and VSV yield, highlighting a viable path to reduce serum dependency across viral vaccine media formulations.

Scale-up often introduces shear stress and process variability. View how low-shear, single-use technology stabilizes media exchange and harvest, ensuring consistent cell quality and predictable performance.

See how a continuous manufacturing platform streamlines production to days, uses real-time quality control, and dramatically cuts costs to accelerate access to new therapies.

Modern platform approaches streamline lentiviral vector design and manufacturing, boosting overall yields while lowering costs to expand global therapeutic access.

A cost-effective analytical approach using digital PCR provides thorough AAV genome evaluation, advancing safer viral vector applications in cell and gene therapy.

Variability reduction programs improve biomanufacturing by controlling raw‑material complexity, optimizing critical attributes, and boosting productivity through data‑driven partnerships.

Review the demonstration of precise, site‑specific integration of a 50 kb multi‑gene construct into human iPSCs, overcoming size limits of traditional genome‑engineering approaches.

Novel manufacturing strategies resolve common scalability and consistency issues, enabling high yields and potent gene-editing tools within a single-day workflow.

Discover how AI can optimize processes, improve efficiency, and enhance the understanding of cellular processes, ultimately leading to more effective and personalized patient treatments.